Moxidectin

The exact presentation is registered in Georgia and FDA-authorised under the same brand; its Georgian kilogram bands correspond to the EU Advocate line rather than the differently bounded US pound bands, which must not be interchanged.

A mature regulatory dossier and controlled laboratory and field programmes support the combination across its broad species-specific flea, mite, nematode and heartworm roles; exact target and repeat schedule remain indication-dependent.

The safety profile is extensively characterised, but the concentrated canine formulation can seriously harm cats; young, underweight, sick or debilitated patients, heartworm-positive animals, oral exposure, MDR1-sensitive dogs and concurrent macrocyclic lactones require strict precautions.

A premeasured monthly pipette is practical and covers several parasite groups, but exact species/concentration selection, direct skin application, drying, licking prevention and indication-specific retreatment intervals are essential.

The exact presentation is registered in Georgia and FDA-authorised under the same brand; its Georgian kilogram bands correspond to the EU Advocate line rather than the differently bounded US pound bands, which must not be interchanged.

A mature regulatory dossier and controlled laboratory and field programmes support the combination across its broad species-specific flea, mite, nematode and heartworm roles; exact target and repeat schedule remain indication-dependent.

The safety profile is extensively characterised, but the concentrated canine formulation can seriously harm cats; young, underweight, sick or debilitated patients, heartworm-positive animals, oral exposure, MDR1-sensitive dogs and concurrent macrocyclic lactones require strict precautions.

A premeasured monthly pipette is practical and covers several parasite groups, but exact species/concentration selection, direct skin application, drying, licking prevention and indication-specific retreatment intervals are essential.

The exact presentation is registered in Georgia and FDA-authorised under the same brand; its Georgian kilogram bands correspond to the EU Advocate line rather than the differently bounded US pound bands, which must not be interchanged.

A mature regulatory dossier and controlled laboratory and field programmes support the combination across its broad species-specific flea, mite, nematode and heartworm roles; exact target and repeat schedule remain indication-dependent.

The safety profile is extensively characterised, but the concentrated canine formulation can seriously harm cats; young, underweight, sick or debilitated patients, heartworm-positive animals, oral exposure, MDR1-sensitive dogs and concurrent macrocyclic lactones require strict precautions.

A premeasured monthly pipette is practical and covers several parasite groups, but exact species/concentration selection, direct skin application, drying, licking prevention and indication-specific retreatment intervals are essential.

The exact presentation is registered in Georgia and FDA-authorised under the same brand; its Georgian kilogram bands correspond to the EU Advocate line rather than the differently bounded US pound bands, which must not be interchanged.

A mature regulatory dossier and controlled laboratory and field programmes support the combination across its broad species-specific flea, mite, nematode and heartworm roles; exact target and repeat schedule remain indication-dependent.

The safety profile is extensively characterised, but the concentrated canine formulation can seriously harm cats; young, underweight, sick or debilitated patients, heartworm-positive animals, oral exposure, MDR1-sensitive dogs and concurrent macrocyclic lactones require strict precautions.

A premeasured monthly pipette is practical and covers several parasite groups, but exact species/concentration selection, direct skin application, drying, licking prevention and indication-specific retreatment intervals are essential.

The exact presentation is registered in Georgia and FDA-authorised under the same brand; its Georgian kilogram bands correspond to the EU Advocate line rather than the differently bounded US pound bands, which must not be interchanged.

A mature regulatory dossier and controlled laboratory and field programmes support the combination across its broad species-specific flea, mite, nematode and heartworm roles; exact target and repeat schedule remain indication-dependent.

The safety profile is extensively characterised, but the concentrated canine formulation can seriously harm cats; young, underweight, sick or debilitated patients, heartworm-positive animals, oral exposure, MDR1-sensitive dogs and concurrent macrocyclic lactones require strict precautions.

A premeasured monthly pipette is practical and covers several parasite groups, but exact species/concentration selection, direct skin application, drying, licking prevention and indication-specific retreatment intervals are essential.

The exact presentation is registered in Georgia and belongs to the mature centrally authorised EU Advocate line, with matching current UK and FDA counterpart documentation.

A mature regulatory dossier and controlled laboratory and field programmes support the combination across its broad species-specific flea, mite, nematode and heartworm roles; exact target and repeat schedule remain indication-dependent.

The safety profile is extensively characterised, but the concentrated canine formulation can seriously harm cats; young, underweight, sick or debilitated patients, heartworm-positive animals, oral exposure, MDR1-sensitive dogs and concurrent macrocyclic lactones require strict precautions.

A premeasured monthly pipette is practical and covers several parasite groups, but exact species/concentration selection, direct skin application, drying, licking prevention and indication-specific retreatment intervals are essential.

The exact 80/8 mg presentation is mature and currently authorised in Europe, but the historical Georgian register row names Advocate while listing imidacloprid alone, so the local composition record is internally incomplete.

A mature regulatory dossier and controlled laboratory and field programmes support the combination across its broad species-specific flea, mite, nematode and heartworm roles; exact target and repeat schedule remain indication-dependent.

The safety profile is extensively characterised, but the concentrated canine formulation can seriously harm cats; young, underweight, sick or debilitated patients, heartworm-positive animals, oral exposure, MDR1-sensitive dogs and concurrent macrocyclic lactones require strict precautions.

A premeasured monthly pipette is practical and covers several parasite groups, but exact species/concentration selection, direct skin application, drying, licking prevention and indication-specific retreatment intervals are essential.

The exact presentation is registered in Georgia and belongs to the mature centrally authorised EU Advocate line, with matching current UK and FDA counterpart documentation.

A mature regulatory dossier and controlled laboratory and field programmes support the combination across its broad species-specific flea, mite, nematode and heartworm roles; exact target and repeat schedule remain indication-dependent.

The safety profile is extensively characterised, but the concentrated canine formulation can seriously harm cats; young, underweight, sick or debilitated patients, heartworm-positive animals, oral exposure, MDR1-sensitive dogs and concurrent macrocyclic lactones require strict precautions.

A premeasured monthly pipette is practical and covers several parasite groups, but exact species/concentration selection, direct skin application, drying, licking prevention and indication-specific retreatment intervals are essential.

The exact feline range is centrally authorised in the EU with current combined official product information and strong indication-specific trials; Georgian registration is shown separately per presentation.

Randomised field and controlled studies show high, sustained efficacy across fleas, ticks and labelled nematodes, including lungworm prevention; the fixed combination is appropriate only when ectoparasite control and another labelled parasite target are needed together.

Generally well tolerated, but transient skin, gastrointestinal and rare neurologic reactions are recognised; young or underweight cats, reproduction, adult heartworm assessment and P-glycoprotein inhibitor combinations require specific precautions.

One whole weight-banded pipette gives broad long-interval coverage, but direct skin placement, prevention of grooming, indication-specific retreatment and pre-treatment parasite-risk assessment are essential.

The exact feline range is centrally authorised in the EU with current combined official product information and strong indication-specific trials; Georgian registration is shown separately per presentation.

Randomised field and controlled studies show high, sustained efficacy across fleas, ticks and labelled nematodes, including lungworm prevention; the fixed combination is appropriate only when ectoparasite control and another labelled parasite target are needed together.

Generally well tolerated, but transient skin, gastrointestinal and rare neurologic reactions are recognised; young or underweight cats, reproduction, adult heartworm assessment and P-glycoprotein inhibitor combinations require specific precautions.

One whole weight-banded pipette gives broad long-interval coverage, but direct skin placement, prevention of grooming, indication-specific retreatment and pre-treatment parasite-risk assessment are essential.

The exact feline range is centrally authorised in the EU with current combined official product information and strong indication-specific trials; Georgian registration is shown separately per presentation.

Randomised field and controlled studies show high, sustained efficacy across fleas, ticks and labelled nematodes, including lungworm prevention; the fixed combination is appropriate only when ectoparasite control and another labelled parasite target are needed together.

Generally well tolerated, but transient skin, gastrointestinal and rare neurologic reactions are recognised; young or underweight cats, reproduction, adult heartworm assessment and P-glycoprotein inhibitor combinations require specific precautions.

One whole weight-banded pipette gives broad long-interval coverage, but direct skin placement, prevention of grooming, indication-specific retreatment and pre-treatment parasite-risk assessment are essential.

Exact strengths have current Georgian registrations and an indefinite Bulgarian authorization with a public product-specific SPC confirming composition, dog-only use and weight bands.

An exact-product report found high activity against several natural infestations, but groups were small, control detail limited and an author was affiliated with the producer. The broad label has moderate, not definitive, clinical support.

A small exact-product study found no measured abnormalities at up to five times the label dose, but cannot exclude uncommon harms. Licking, overdose, reproduction, age or illness, other antiparasitics, ear integrity and environmental exposure need safeguards.

A whole weight-banded pipette simplifies routine dosing. Direct-to-skin placement, prevention of licking, keeping dry and separation until dry add practical burden.

Exact strengths have current Georgian registrations and an indefinite Bulgarian authorization with a public product-specific SPC confirming composition, dog-only use and weight bands.

An exact-product report found high activity against several natural infestations, but groups were small, control detail limited and an author was affiliated with the producer. The broad label has moderate, not definitive, clinical support.

A small exact-product study found no measured abnormalities at up to five times the label dose, but cannot exclude uncommon harms. Licking, overdose, reproduction, age or illness, other antiparasitics, ear integrity and environmental exposure need safeguards.

A whole weight-banded pipette simplifies routine dosing. Direct-to-skin placement, prevention of licking, keeping dry and separation until dry add practical burden.

Exact strengths have current Georgian registrations and an indefinite Bulgarian authorization with a public product-specific SPC confirming composition, dog-only use and weight bands.

An exact-product report found high activity against several natural infestations, but groups were small, control detail limited and an author was affiliated with the producer. The broad label has moderate, not definitive, clinical support.

A small exact-product study found no measured abnormalities at up to five times the label dose, but cannot exclude uncommon harms. Licking, overdose, reproduction, age or illness, other antiparasitics, ear integrity and environmental exposure need safeguards.

A whole weight-banded pipette simplifies routine dosing. Direct-to-skin placement, prevention of licking, keeping dry and separation until dry add practical burden.

Exact strengths have current Georgian registrations and an indefinite Bulgarian authorization with a public product-specific SPC confirming composition, dog-only use and weight bands.

An exact-product report found high activity against several natural infestations, but groups were small, control detail limited and an author was affiliated with the producer. The broad label has moderate, not definitive, clinical support.

A small exact-product study found no measured abnormalities at up to five times the label dose, but cannot exclude uncommon harms. Licking, overdose, reproduction, age or illness, other antiparasitics, ear integrity and environmental exposure need safeguards.

A whole weight-banded pipette simplifies routine dosing. Direct-to-skin placement, prevention of licking, keeping dry and separation until dry add practical burden.

Exact strengths have current Georgian registrations and an indefinite Bulgarian authorization with a public product-specific SPC confirming composition, dog-only use and weight bands.

An exact-product report found high activity against several natural infestations, but groups were small, control detail limited and an author was affiliated with the producer. The broad label has moderate, not definitive, clinical support.

A small exact-product study found no measured abnormalities at up to five times the label dose, but cannot exclude uncommon harms. Licking, overdose, reproduction, age or illness, other antiparasitics, ear integrity and environmental exposure need safeguards.

A whole weight-banded pipette simplifies routine dosing. Direct-to-skin placement, prevention of licking, keeping dry and separation until dry add practical burden.

Exact strengths have current Georgian registrations and an indefinite Bulgarian register entry. Confidence is reduced because the Quadro K page links to the Quadro C dog SPC rather than a K-specific feline SPC; the exact K instruction is available from the manufacturer.

An exact-product report found high activity against several natural infestations, but groups were small, control detail limited and an author was affiliated with the producer. The broad label has moderate, not definitive, clinical support.

A small exact-product study found no measured abnormalities at up to five times the label dose, but cannot exclude uncommon harms. Licking, overdose, reproduction, age or illness, other antiparasitics, ear integrity and environmental exposure need safeguards.

A whole weight-banded pipette simplifies routine dosing. Direct-to-skin placement, prevention of licking, keeping dry and separation until dry add practical burden.

Exact strengths have current Georgian registrations and an indefinite Bulgarian register entry. Confidence is reduced because the Quadro K page links to the Quadro C dog SPC rather than a K-specific feline SPC; the exact K instruction is available from the manufacturer.

An exact-product report found high activity against several natural infestations, but groups were small, control detail limited and an author was affiliated with the producer. The broad label has moderate, not definitive, clinical support.

A small exact-product study found no measured abnormalities at up to five times the label dose, but cannot exclude uncommon harms. Licking, overdose, reproduction, age or illness, other antiparasitics, ear integrity and environmental exposure need safeguards.

A whole weight-banded pipette simplifies routine dosing. Direct-to-skin placement, prevention of licking, keeping dry and separation until dry add practical burden.

Exact strengths have current Georgian registrations and an indefinite Bulgarian authorization with a public SPC. Confidence is reduced because the BFSA Tabs SPC contains a topical pharmacokinetic passage inconsistent with an oral-tablet document.

The combination is plausible and has a small exact-product tolerability study, but direct efficacy evidence is sparse. A five-dog cestode report required repeat dosing for full clearance; robust independent trials do not validate every broad claim in both species.

A small exact-product study found no measured abnormalities at up to five times the label dose, but cannot exclude uncommon harms. Macrocyclic-lactone susceptibility, age, health, reproduction, interactions and adverse reactions need screening.

Weight-banded tablets and half-tablet increments simplify routine dosing, but repeated or diagnosis-specific schedules must not be inferred from a one-dose calculator.

Exact strengths have current Georgian registrations and an indefinite Bulgarian authorization with a public SPC. Confidence is reduced because the BFSA Tabs SPC contains a topical pharmacokinetic passage inconsistent with an oral-tablet document.

The combination is plausible and has a small exact-product tolerability study, but direct efficacy evidence is sparse. A five-dog cestode report required repeat dosing for full clearance; robust independent trials do not validate every broad claim in both species.

A small exact-product study found no measured abnormalities at up to five times the label dose, but cannot exclude uncommon harms. Macrocyclic-lactone susceptibility, age, health, reproduction, interactions and adverse reactions need screening.

Weight-banded tablets and half-tablet increments simplify routine dosing, but repeated or diagnosis-specific schedules must not be inferred from a one-dose calculator.

Exact strengths have current Georgian registrations and an indefinite Bulgarian authorization with a public SPC. Confidence is reduced because the BFSA Tabs SPC contains a topical pharmacokinetic passage inconsistent with an oral-tablet document.

The combination is plausible and has a small exact-product tolerability study, but direct efficacy evidence is sparse. A five-dog cestode report required repeat dosing for full clearance; robust independent trials do not validate every broad claim in both species.

A small exact-product study found no measured abnormalities at up to five times the label dose, but cannot exclude uncommon harms. Macrocyclic-lactone susceptibility, age, health, reproduction, interactions and adverse reactions need screening.

Weight-banded tablets and half-tablet increments simplify routine dosing, but repeated or diagnosis-specific schedules must not be inferred from a one-dose calculator.

Exact strengths have current Georgian registrations and an indefinite Bulgarian authorization with a public SPC. Confidence is reduced because the BFSA Tabs SPC contains a topical pharmacokinetic passage inconsistent with an oral-tablet document.

The combination is plausible and has a small exact-product tolerability study, but direct efficacy evidence is sparse. A five-dog cestode report required repeat dosing for full clearance; robust independent trials do not validate every broad claim in both species.

A small exact-product study found no measured abnormalities at up to five times the label dose, but cannot exclude uncommon harms. Macrocyclic-lactone susceptibility, age, health, reproduction, interactions and adverse reactions need screening.

Weight-banded tablets and half-tablet increments simplify routine dosing, but repeated or diagnosis-specific schedules must not be inferred from a one-dose calculator.

Exact strengths have current Georgian registrations and an indefinite Bulgarian authorization with a public SPC. Confidence is reduced because the BFSA Tabs SPC contains a topical pharmacokinetic passage inconsistent with an oral-tablet document.

The combination is plausible and has a small exact-product tolerability study, but direct efficacy evidence is sparse. A five-dog cestode report required repeat dosing for full clearance; robust independent trials do not validate every broad claim in both species.

A small exact-product study found no measured abnormalities at up to five times the label dose, but cannot exclude uncommon harms. Macrocyclic-lactone susceptibility, age, health, reproduction, interactions and adverse reactions need screening.

Weight-banded tablets and half-tablet increments simplify routine dosing, but repeated or diagnosis-specific schedules must not be inferred from a one-dose calculator.

Exact strengths have current Georgian registrations and an indefinite Bulgarian authorization with a public SPC. Confidence is reduced because the BFSA Tabs SPC contains a topical pharmacokinetic passage inconsistent with an oral-tablet document.

The combination is plausible and has a small exact-product tolerability study, but direct efficacy evidence is sparse. A five-dog cestode report required repeat dosing for full clearance; robust independent trials do not validate every broad claim in both species.

A small exact-product study found no measured abnormalities at up to five times the label dose, but cannot exclude uncommon harms. Macrocyclic-lactone susceptibility, age, health, reproduction, interactions and adverse reactions need screening.

Weight-banded tablets and half-tablet increments simplify routine dosing, but repeated or diagnosis-specific schedules must not be inferred from a one-dose calculator.

Exact strengths have current Georgian registrations and an indefinite Bulgarian authorization with a public SPC. Confidence is reduced because the BFSA Tabs SPC contains a topical pharmacokinetic passage inconsistent with an oral-tablet document.

The combination is plausible and has a small exact-product tolerability study, but direct efficacy evidence is sparse. A five-dog cestode report required repeat dosing for full clearance; robust independent trials do not validate every broad claim in both species.

A small exact-product study found no measured abnormalities at up to five times the label dose, but cannot exclude uncommon harms. Macrocyclic-lactone susceptibility, age, health, reproduction, interactions and adverse reactions need screening.

Weight-banded tablets and half-tablet increments simplify routine dosing, but repeated or diagnosis-specific schedules must not be inferred from a one-dose calculator.

The exact strengths are actively registered in Georgia, a regulator-hosted Moldovan leaflet independently corroborates identity and use, and multiple exact-product studies are published. However, no EMA/FDA-style public assessment or transparent full dossier was found, and much of the evidence is manufacturer-linked.

Exact-product studies report high efficacy against selected naturally or experimentally infested ectoparasites and provide pharmacokinetic support for all three actives. Study groups are generally small, comparator, blinding and sponsor independence are limited, and the very broad label spectrum and every claimed duration are not validated equally well.

A 30-dog tolerance study found no important effect at the therapeutic regimen, but five consecutive daily double doses caused salivation, vomiting, incoordination, depression or mydriasis in 30% of dogs. The exact label has extensive age, reproductive, disease, MDR1/macrolactone and drug-combination restrictions; uncommon-event and diverse-patient safety remain incompletely defined.

Quarter-tablet scoring and explicit small-dog cells make this the most flexible presentation. It must still be given with or just after food and only for printed weight cells; the table contains gaps and alternative-strength overlaps that must not be interpolated.

The exact strengths are actively registered in Georgia, a regulator-hosted Moldovan leaflet independently corroborates identity and use, and multiple exact-product studies are published. However, no EMA/FDA-style public assessment or transparent full dossier was found, and much of the evidence is manufacturer-linked.

Exact-product studies report high efficacy against selected naturally or experimentally infested ectoparasites and provide pharmacokinetic support for all three actives. Study groups are generally small, comparator, blinding and sponsor independence are limited, and the very broad label spectrum and every claimed duration are not validated equally well.

A 30-dog tolerance study found no important effect at the therapeutic regimen, but five consecutive daily double doses caused salivation, vomiting, incoordination, depression or mydriasis in 30% of dogs. The exact label has extensive age, reproductive, disease, MDR1/macrolactone and drug-combination restrictions; uncommon-event and diverse-patient safety remain incompletely defined.

Quarter-tablet scoring provides useful flexibility across several explicit cells, but the official table is discontinuous and extends this presentation beyond its marketing subtitle. Select the printed cell rather than inferring a continuous mg/kg rule or substituting another strength.

The exact strengths are actively registered in Georgia, a regulator-hosted Moldovan leaflet independently corroborates identity and use, and multiple exact-product studies are published. However, no EMA/FDA-style public assessment or transparent full dossier was found, and much of the evidence is manufacturer-linked.

Exact-product studies report high efficacy against selected naturally or experimentally infested ectoparasites and provide pharmacokinetic support for all three actives. Study groups are generally small, comparator, blinding and sponsor independence are limited, and the very broad label spectrum and every claimed duration are not validated equally well.

A 30-dog tolerance study found no important effect at the therapeutic regimen, but five consecutive daily double doses caused salivation, vomiting, incoordination, depression or mydriasis in 30% of dogs. The exact label has extensive age, reproductive, disease, MDR1/macrolactone and drug-combination restrictions; uncommon-event and diverse-patient safety remain incompletely defined.

Oral dosing and quarter-tablet scoring are convenient, but the large-dog table has no 21-25 kg cell for this strength and requires another strength there; above 60 kg the label uses combinations not supplied by this single presentation. These gaps materially increase selection and pack-management burden.

Every exact strength is registered in Georgia and the combination has current central EU/UK and FDA authorisations with detailed public dossiers.

Large controlled field and laboratory programmes support fleas, ticks, gastrointestinal nematodes and heartworm prevention, with additional labelled mite and lungworm roles; efficacy depends on matching the combined-indication gate and schedule.

The profile is extensively studied but combines isoxazoline neurological risk with macrocyclic-lactone precautions, potential reactions in heavily microfilaraemic dogs and strict dose discipline in MDR1-sensitive breeds.

One palatable monthly chew integrates several parasite targets, but correct use requires heartworm testing where indicated, exact weight-band selection and confirmation that a combination product is clinically justified.

Every exact strength is registered in Georgia and the combination has current central EU/UK and FDA authorisations with detailed public dossiers.

Large controlled field and laboratory programmes support fleas, ticks, gastrointestinal nematodes and heartworm prevention, with additional labelled mite and lungworm roles; efficacy depends on matching the combined-indication gate and schedule.

The profile is extensively studied but combines isoxazoline neurological risk with macrocyclic-lactone precautions, potential reactions in heavily microfilaraemic dogs and strict dose discipline in MDR1-sensitive breeds.

One palatable monthly chew integrates several parasite targets, but correct use requires heartworm testing where indicated, exact weight-band selection and confirmation that a combination product is clinically justified.

Every exact strength is registered in Georgia and the combination has current central EU/UK and FDA authorisations with detailed public dossiers.

Large controlled field and laboratory programmes support fleas, ticks, gastrointestinal nematodes and heartworm prevention, with additional labelled mite and lungworm roles; efficacy depends on matching the combined-indication gate and schedule.

The profile is extensively studied but combines isoxazoline neurological risk with macrocyclic-lactone precautions, potential reactions in heavily microfilaraemic dogs and strict dose discipline in MDR1-sensitive breeds.

One palatable monthly chew integrates several parasite targets, but correct use requires heartworm testing where indicated, exact weight-band selection and confirmation that a combination product is clinically justified.

Every exact strength is registered in Georgia and the combination has current central EU/UK and FDA authorisations with detailed public dossiers.

Large controlled field and laboratory programmes support fleas, ticks, gastrointestinal nematodes and heartworm prevention, with additional labelled mite and lungworm roles; efficacy depends on matching the combined-indication gate and schedule.

The profile is extensively studied but combines isoxazoline neurological risk with macrocyclic-lactone precautions, potential reactions in heavily microfilaraemic dogs and strict dose discipline in MDR1-sensitive breeds.

One palatable monthly chew integrates several parasite targets, but correct use requires heartworm testing where indicated, exact weight-band selection and confirmation that a combination product is clinically justified.

Every exact strength is registered in Georgia and the combination has current central EU/UK and FDA authorisations with detailed public dossiers.

Large controlled field and laboratory programmes support fleas, ticks, gastrointestinal nematodes and heartworm prevention, with additional labelled mite and lungworm roles; efficacy depends on matching the combined-indication gate and schedule.

The profile is extensively studied but combines isoxazoline neurological risk with macrocyclic-lactone precautions, potential reactions in heavily microfilaraemic dogs and strict dose discipline in MDR1-sensitive breeds.

One palatable monthly chew integrates several parasite targets, but correct use requires heartworm testing where indicated, exact weight-band selection and confirmation that a combination product is clinically justified.

Every exact strength is registered in Georgia and the combination has current central EU/UK and FDA authorisations with detailed public dossiers.

Large controlled field and laboratory programmes support fleas, ticks, gastrointestinal nematodes and heartworm prevention, with additional labelled mite and lungworm roles; efficacy depends on matching the combined-indication gate and schedule.

The profile is extensively studied but combines isoxazoline neurological risk with macrocyclic-lactone precautions, potential reactions in heavily microfilaraemic dogs and strict dose discipline in MDR1-sensitive breeds.

One palatable monthly chew integrates several parasite targets, but correct use requires heartworm testing where indicated, exact weight-band selection and confirmation that a combination product is clinically justified.